{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T08:08:56Z","timestamp":1784621336327,"version":"3.55.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,9]],"date-time":"2019-05-09T00:00:00Z","timestamp":1557360000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005693","name":"Parent Project Muscular Dystrophy","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100005693","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13023-019-1069-6","type":"journal-article","created":{"date-parts":[[2019,5,9]],"date-time":"2019-05-09T14:05:57Z","timestamp":1557410757000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Priorities when deciding on participation in early-phase gene therapy trials for Duchenne muscular dystrophy: a best\u2013worst scaling experiment in caregivers and adult patients"],"prefix":"10.1186","volume":"14","author":[{"given":"Ryan S.","family":"Paquin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Mansfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brennan","family":"Mange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Beaverson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Ganot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy Strong","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Rensch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Ricotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo J.","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alesia","family":"Sadosky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward C.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3053-7453","authenticated-orcid":false,"given":"Holly L.","family":"Peay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,9]]},"reference":[{"key":"1069_CR1","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/ana.23528","volume":"71","author":"JR Mendell","year":"2012","unstructured":"Mendell JR, Shilling C, Leslie ND, et al. Evidence-based path to newborn screening for Duchenne muscular dystrophy. Ann Neurol. 2012;71:304\u201313.","journal-title":"Ann Neurol"},{"issue":"1","key":"1069_CR2","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","volume":"9","author":"K Bushby","year":"2010","unstructured":"Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010;9(1):77\u201393.","journal-title":"Lancet Neurol"},{"issue":"3","key":"1069_CR3","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.ncl.2014.05.002","volume":"32","author":"KM Flanigan","year":"2014","unstructured":"Flanigan KM. Duchenne and Becker muscular dystrophies. Neurol Clin. 2014;32(3):671\u201388 viii.","journal-title":"Neurol Clin"},{"issue":"1","key":"1069_CR4","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13023-017-0631-3","volume":"12","author":"S Ryder","year":"2017","unstructured":"Ryder S, Leadley RM, Armstrong N, Westwood M, de Kock S, Butt T, et al. The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review. Orphanet J Rare Dis. 2017;12(1):79.","journal-title":"Orphanet J Rare Dis"},{"key":"1069_CR5","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.nmd.2015.09.012","volume":"25","author":"E Landfeldt","year":"2015","unstructured":"Landfeldt E, Mayhew A, Eagle M, Lindgren P, Bell CF, Guglieri M, et al. Development and psychometric analysis of the Duchenne muscular dystrophy functional ability self-assessment tool (DMDSAT). Neuromuscul Disord. 2015;25:937\u201344.","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"1069_CR6","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00415-017-8406-2","volume":"264","author":"C Otto","year":"2017","unstructured":"Otto C, Steffensen BF, H\u00f8jberg AL, Barkmann C, Rahbek J, Ravens-Sieberer U, et al. Predictors of health-related quality of life in boys with Duchenne muscular dystrophy from six European countries. J Neurol. 2017;264(4):709\u201323.","journal-title":"J Neurol"},{"issue":"6","key":"1069_CR7","doi-asserted-by":"publisher","first-page":"e1559","DOI":"10.1542\/peds.2012-0858","volume":"130","author":"K Uzark","year":"2012","unstructured":"Uzark K, King E, Cripe L, Spicer R, Sage J, Kinnett K, et al. Health-related quality of life in children and adolescents with Duchenne muscular dystrophy. Pediatrics. 2012;130(6):e1559\u201366.","journal-title":"Pediatrics."},{"issue":"5","key":"1069_CR8","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1007\/s00415-016-8080-9","volume":"263","author":"E Landfeldt","year":"2016","unstructured":"Landfeldt E, Lindgren P, Bell CF, Guglieri M, Straub V, Lochm\u00fcller H, et al. Quantifying the burden of caregiving in Duchenne muscular dystrophy. J Neurol. 2016;263(5):906\u201315.","journal-title":"J Neurol"},{"issue":"5","key":"1069_CR9","doi-asserted-by":"publisher","first-page":"e1030","DOI":"10.1542\/peds.2008-0582","volume":"122","author":"J Hatzmann","year":"2008","unstructured":"Hatzmann J, Heymans HS, Ferrer-i-Carbonell A, van Praag BM, Grootenhuis MA. Hidden consequences of success in pediatrics: parental health-related quality of life--results from the care project. Pediatrics. 2008;122(5):e1030\u20138.","journal-title":"Pediatrics."},{"issue":"5","key":"1069_CR10","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1111\/j.1365-2524.2010.00930.x","volume":"18","author":"A Kenneson","year":"2010","unstructured":"Kenneson A, Bobo JK. The effect of caregiving on women in families with Duchenne\/Becker muscular dystrophy. Health Soc Care Community. 2010;18(5):520\u20138.","journal-title":"Health Soc Care Community"},{"issue":"1","key":"1069_CR11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/mus.24503","volume":"52","author":"L Magliano","year":"2015","unstructured":"Magliano L, Patalano M, Sagliocchi A, Scutifero M, Zaccaro A, D'angelo MG, et al. Burden, professional support, and social network in families of children and young adults with muscular dystrophies. Muscle Nerve. 2015;52(1):13\u201321.","journal-title":"Muscle Nerve"},{"issue":"12","key":"1069_CR12","doi-asserted-by":"publisher","first-page":"988","DOI":"10.3109\/09638288.2011.628738","volume":"34","author":"RF Pangalila","year":"2012","unstructured":"Pangalila RF, van den Bos GA, Stam HJ, van Exel NJ, Brouwer WB, Roebroeck ME. Subjective caregiver burden of parents of adults with Duchenne muscular dystrophy. Disabil Rehabil. 2012;34(12):988\u201396.","journal-title":"Disabil Rehabil"},{"issue":"5","key":"1069_CR13","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/ejhg.2015.189","volume":"24","author":"HL Peay","year":"2016","unstructured":"Peay HL, Meiser B, Kinnett K, Furlong P, Porter K, Tibben A. Mothers' psychological adaptation to Duchenne\/Becker muscular dystrophy. Eur J Hum Genet. 2016;24(5):633\u20137.","journal-title":"Eur J Hum Genet"},{"issue":"2","key":"1069_CR14","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s10897-015-9872-2","volume":"25","author":"HL Peay","year":"2016","unstructured":"Peay HL, Hollin IL, Bridges JF. Prioritizing parental worry associated with Duchenne muscular dystrophy using best-worst scaling. J Genet Couns. 2016;25(2):305\u201313.","journal-title":"J Genet Couns"},{"issue":"6","key":"1069_CR15","doi-asserted-by":"publisher","first-page":"368","DOI":"10.2146\/news170020","volume":"74","author":"K Traynor","year":"2017","unstructured":"Traynor K. Deflazacort approved for Duchenne muscular dystrophy. Am J Health Syst Pharm. 2017;74(6):368.","journal-title":"Am J Health Syst Pharm"},{"key":"1069_CR16","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.cct.2017.04.008","volume":"58","author":"M Guglieri","year":"2017","unstructured":"Guglieri M, Bushby K, McDermott MP, Hart KA, Tawil R, Martens WB, et al. Developing standardized corticosteroid treatment for Duchenne muscular dystrophy. Contemp Clin Trials. 2017;58:34\u20139.","journal-title":"Contemp Clin Trials"},{"issue":"1","key":"1069_CR17","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1002\/ana.24842","volume":"81","author":"EF Unger","year":"2017","unstructured":"Unger EF, Califf RM. Regarding \u201cEteplirsen for the treatment of Duchenne muscular dystrophy\u201d. Ann Neurol. 2017;81(1):162\u20134.","journal-title":"Ann Neurol"},{"issue":"2","key":"1069_CR18","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1080\/14712598.2017.1271872","volume":"17","author":"EH Niks","year":"2017","unstructured":"Niks EH, Aartsma-Rus A. Exon skipping: a first in class strategy for Duchenne muscular dystrophy. Expert Opin Biol Ther. 2017;17(2):225\u201336.","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"1069_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/nat.2016.0657","volume":"27","author":"A Aartsma-Rus","year":"2017","unstructured":"Aartsma-Rus A, Krieg AM. FDA approves Eteplirsen for Duchenne muscular dystrophy: the next chapter in the Eteplirsen saga. Nucleic Acid Ther. 2017;27(1):1\u20133.","journal-title":"Nucleic Acid Ther"},{"issue":"4","key":"1069_CR20","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/phar.1909","volume":"37","author":"AM Reinig","year":"2017","unstructured":"Reinig AM, Mirzaei S, Berlau DJ. Advances in the treatment of Duchenne muscular dystrophy: new and emerging pharmacotherapies. Pharmacotherapy. 2017;37(4):492\u20139.","journal-title":"Pharmacotherapy."},{"key":"1069_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms16105","volume":"8","author":"C Le Guiner","year":"2017","unstructured":"Le Guiner C, Servais L, Montus M, Larcher T, Fraysse B, Moullec S, et al. Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy. Nat Commun. 2017;8:16105.","journal-title":"Nat Commun"},{"issue":"5","key":"1069_CR22","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/j.ymthe.2017.02.019","volume":"25","author":"JR Chamberlain","year":"2017","unstructured":"Chamberlain JR, Chamberlain JS. Progress toward gene therapy for Duchenne muscular dystrophy. Mol Ther. 2017;25(5):1125\u201331.","journal-title":"Mol Ther"},{"issue":"11","key":"1069_CR23","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1038\/mt.2012.181","volume":"20","author":"A Vulin","year":"2012","unstructured":"Vulin A, Barth\u00e9l\u00e9my I, Goyenvalle A, Thibaud JL, Beley C, Griffith G, et al. Muscle function recovery in golden retriever muscular dystrophy after AAV1-U7 exon skipping. Mol Ther. 2012;20(11):2120\u201333.","journal-title":"Mol Ther"},{"key":"1069_CR24","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/2044-5040-4-18","volume":"4","author":"JN Kornegay","year":"2014","unstructured":"Kornegay JN, Peterson JM, Bogan DJ, Kline W, Bogan JR, Dow JL, et al. NBD delivery improves the disease phenotype of the golden retriever model of Duchenne muscular dystrophy. Skelet Muscle. 2014;4:18.","journal-title":"Skelet Muscle"},{"issue":"7","key":"1069_CR25","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1089\/hum.2018.012","volume":"29","author":"D Duan","year":"2018","unstructured":"Duan D. Micro-dystrophin gene therapy goes systemic in Duchenne muscular dystrophy patients. Hum Gene Ther. 2018;29(7):733\u20136.","journal-title":"Hum Gene Ther"},{"issue":"1","key":"1069_CR26","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1177\/1740774513512726","volume":"11","author":"HL Peay","year":"2014","unstructured":"Peay HL, Tibben A, Fisher T, Brenna E, Biesecker BB. Expectations and experiences of investigators and parents involved in a clinical trial for Duchenne\/Becker muscular dystrophy. Clin Trials. 2014;11(1):77\u201385. Available from. https:\/\/doi.org\/10.1177\/1740774513512726 .","journal-title":"Clin Trials."},{"key":"1069_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cct.2015.11.006","volume":"46","author":"HL Peay","year":"2016","unstructured":"Peay HL, Scharff H, Tibben A, Wilfond B, Bowie J, Johnson J, et al. \u201cWatching time tick by\u2026\u201d: decision making for Duchenne muscular dystrophy trials. Contemp Clin Trials. 2016;46:1\u20136. Available from, DOI: 10.1016\/j.cct.2015.11.006, 10.1016\/j.cct.2015.11.006.","journal-title":"Contemp Clin Trials."},{"issue":"1","key":"1069_CR28","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s40271-014-0104-x","volume":"8","author":"IL Hollin","year":"2015","unstructured":"Hollin IL, Peay HL, Bridges JF. Caregiver preferences for emerging duchenne muscular dystrophy treatments: a comparison of best-worst scaling and conjoint analysis. Patient. 2015;8(1):19\u201327.","journal-title":"Patient."},{"issue":"5","key":"1069_CR29","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1002\/mus.25411","volume":"55","author":"IL Hollin","year":"2017","unstructured":"Hollin IL, Peay HL, Apkon SD, Bridges JFP. Patient-centered benefit-risk assessment in duchenne muscular dystrophy. Muscle Nerve. 2017;55(5):626\u201334.","journal-title":"Muscle Nerve"},{"issue":"5","key":"1069_CR30","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.clinthera.2014.04.011","volume":"36","author":"HL Peay","year":"2014","unstructured":"Peay HL, Hollin I, Fischer R, Bridges JF. A community-engaged approach to quantifying caregiver preferences for the benefits and risks of emerging therapies for Duchenne muscular dystrophy. Clin Ther. 2014;36(5):624\u201337.","journal-title":"Clin Ther"},{"key":"1069_CR31","volume-title":"Online Survey Software and Hosting Platform [Computer program]","author":"Qualtrics","year":"2018","unstructured":"Qualtrics. Online Survey Software and Hosting Platform [Computer program]. Provo: Qualtrics; 2018."},{"key":"1069_CR32","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9781107337855","volume-title":"Best-worst scaling: theory, methods and applications","author":"JJ Louviere","year":"2015","unstructured":"Louviere JJ, Flynn TN, Marley AAJ. Best-worst scaling: theory, methods and applications. Cambridge: Cambridge University Press; 2015."},{"key":"1069_CR33","doi-asserted-by":"publisher","unstructured":"Peay H, Fischer R, Beaverson K, Morris C, Hesterlee S, Ricotti V et al. Parent and adult patient attitudes about gene therapy as a therapeutic option for Duchenne muscular dystrophy. Value Health. 2018;21(Suppl 1):S256. Available from, DOI: https:\/\/doi.org\/10.1016\/j.jval.2018.04.1781","DOI":"10.1016\/j.jval.2018.04.1781"},{"key":"1069_CR34","volume-title":"The MaxDiff System Technical Paper: Version 8","author":"Sawtooth Software","year":"2013","unstructured":"Sawtooth Software. The MaxDiff System Technical Paper: Version 8. Orem: Sawtooth Software, Inc; 2013."},{"issue":"1","key":"1069_CR35","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jhealeco.2006.04.002","volume":"26","author":"TN Flynn","year":"2007","unstructured":"Flynn TN, Louviere JJ, Peters TJ, Coast J. Best-worst scaling: what it can do for health care research and how to do it. J Health Econ. 2007;26(1):171\u201389. Available from. https:\/\/doi.org\/10.1016\/j.jhealeco.2006.04.002 .","journal-title":"J Health Econ"},{"key":"1069_CR36","volume-title":"Stata Statistical Software, Release 15.0 [computer program]","author":"StataCorp","year":"2017","unstructured":"StataCorp. Stata Statistical Software, Release 15.0 [computer program]. College Station: StataCorp LP; 2017."},{"issue":"3","key":"1069_CR37","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1586\/erp.10.29","volume":"10","author":"TN Flynn","year":"2010","unstructured":"Flynn TN. Valuing citizen and patient preferences in health: recent developments in three types of best\u2013worst scaling. Expert Rev Pharmacoeconomics Outcomes Res. 2010;10(3):259\u201367.","journal-title":"Expert Rev Pharmacoeconomics Outcomes Res"},{"issue":"2","key":"1069_CR38","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1007\/s10897-017-0190-8","volume":"27","author":"RR Moultrie","year":"2018","unstructured":"Moultrie RR, Lewis MA, Paquin RS, Lucas A, Jarecki J, Peay HL. An evidence-based, community-engaged approach to develop an interactive deliberation tool for pediatric neuromuscular trials. J Genet Couns. 2018;27(2):416\u201325. Available from. https:\/\/doi.org\/10.1007\/s10897-017-0190-8 .","journal-title":"J Genet Couns"},{"issue":"2","key":"1069_CR39","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1017\/S1930297500005052","volume":"8","author":"JR Doyle","year":"2013","unstructured":"Doyle JR. Survey of time preference, delay discounting models. Judgm Decis Mak. 2013;8(2):116\u201335.","journal-title":"Judgm Decis Mak"},{"issue":"2","key":"1069_CR40","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1177\/1740774517751118","volume":"15","author":"HL Peay","year":"2018","unstructured":"Peay HL, Biesecker BB, Wilfond BS, Jarecki J, Umstead KL, Escolar DM, et al. Barriers and facilitators to clinical trial participation among parents of children with pediatric neuromuscular disorders. Clin Trials. 2018;15(2):139\u201348. Available from. https:\/\/doi.org\/10.1177\/1740774517751118 .","journal-title":"Clin Trials"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-019-1069-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-019-1069-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-019-1069-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T12:02:57Z","timestamp":1694865777000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-019-1069-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,9]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1069"],"URL":"https:\/\/doi.org\/10.1186\/s13023-019-1069-6","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,9]]},"assertion":[{"value":"27 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 information"}},{"value":"The study protocol received IRB review and approval from RTI International\u2019s Committee for the Protection of Human Subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RP\u2013 Declares no conflict of interest.RF\u2013 Full-time employee of Parent Project Muscular Dystrophy, which receives funding from Solid Bioscience and Pfizer in support of preference research programs.CM (1)\u2013 Declares no conflict of interest.BM \u2013 Declares no conflict of interest.KB \u2013 Full-time employee of Pfizer Inc. with stock holdings related to employment.AG \u2013 Employee and co-founder of Sold Biosciences, with stock holdings related to employment.AM \u2013 Declares no conflict of interest.CM (2)\u2013 Employee of Solid Biosciences and former employee of Pfizer, with stock holdings related to employment.CR \u2013 Declares no conflict of interest.VR \u2013 Employee of Solid Biosciences with stock holdings related to employment.LR \u2013 Full-time employee of Pfizer Inc. with stock holdings related to employment.AS \u2013 Full-time employee of Pfizer Inc. with stock holdings related to employment.ECS \u2013 Receives salary support from Pfizer Inc. for role as PI on a gene therapy trial.HP \u2013 Declares no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"102"}}